Tonix shares fell 5.3% after earnings, suggesting investors were not reassured by early launch momentum. While TONMYA sales grew, the launch remains in an early stage, and the transcript points to gross-to-net fluctuations and a newly filed generic challenge as key risks.
Tonix Pharmaceuticals' stock gained modestly by 2.6% post-earnings, reflecting steady early traction in the TONMYA launch but no clear upside surprise. While sales growth was impressive quarter-over-quarter, cautious coverage and access expansion temper enthusiasm and suggest the story remains in early innings.